BMS-824393

BMS-824393 is an oral, small molecule inhibitor developed by Bristol Myers Squibb for the treatment of chronic hepatitis C virus (HCV) infection, specifically targeting genotype 1. It acts as a potent and highly selective inhibitor of the HCV nonstructural protein 5A (NS5A), a multifunctional protein essential for viral replication. BMS-824393 demonstrated picomolar in vitro potency against HCV genotypes 1a and 1b, with broad genotypic coverage. Clinical studies showed that BMS-824393 was well-tolerated in both healthy subjects and patients with chronic HCV infection, exhibiting a pharmacokinetic profile supportive of once-daily dosing[1][4][5][8].